DGIdb - TRETINOIN Drug Record

TRETINOIN chembl:CHEMBL38 ApprovedAntineoplasticImmunotherapy

Alternate Names:

RENOVA
ALTRENO
TRETINOIN
ATRALIN
TRETIN-X
ACTICIN
RETIN-A MICRO
RETIN-A
RETINOIC ACID
RETIN-A-MICRO
AVITA
NSC-122758
VESANOID
TRETINOINE (FRENCH)
TRETINOINUM
AVITA®
ALL-TRANS-TRETINOIN
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOIC ACID
VITAMIN A ACID
ALL-TRANS-BETA-RETINOIC ACID
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOATE
3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENE-1-YL)-2,4,6,8-NONATETRAENOIC ACID (ECL)
ALL-(E)-RETINOATE
ALL TRANS-RETINOIC ACID
3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOIC ACID
TRETINOINE (FRENCH) (EINECS)
STIEVA-A
BETA-RETINOATE
ACIDE RETINOIQUE (FRENCH) (DSL)
3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOATE
ALL TRANS RETINOIC ACID
ACIDE RETINOIQUE (FRENCH)
RETINOATE
AGN 100335
ALL-(E)-RETINOIC ACID
TRETINOIN、ATRA
TRETIN M
EUDYNA
TRANS-RETINOATE
TRANS-RETINOIC ACID
RENOVA®
ATRA
RETIONIC ACID
TRETINOINA
ALL-TRANS-VITAMIN A ACID
ALL-TRANS-VITAMIN A1 ACID
TRÉTINOÏNE
ALL-TRANS-RETINOIC ACID
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)NONA-2,4,6,8-TETRAENOIC ACID
ALL-TRANS-RETINOIC ACID (ATRA)
BETA-RETINOIC ACID
RO 1-5488
rxcui:10753
pubchem.compound:444795
chembl:CHEMBL38
drugbank:00755
chemidplus:302-79-4

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of acne
Drug Class	keratolytic agents
Year of Approval	1988
Drug Class	antineoplastic agents

(7 More Sources)

Publications:

Schrage et al., 2006, Macrophages and neurons are targets of retinoic acid signaling after spinal cord contusion injury., Eur. J. Neurosci.
Redfern, 2004, Enhancing enhancers: new complexities in the retinoid regulation of gene expression., Biochem. J.
Stafslien et al., 2007, Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay., Mol. Cell. Endocrinol.
Hoegberg et al., 2005, Retinoid status and responsiveness to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking retinoid binding protein or retinoid receptor forms., Chem. Biol. Interact.
Nagasawa et al., 2005, Effect of retinoic acid on murine preosteoblastic MC3T3-E1 cells., J. Nutr. Sci. Vitaminol.
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Reddy et al., 1992, Characterization and purification of human retinoic acid receptor-gamma 1 overexpressed in the baculovirus-insect cell system., Biochem. J.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Kamei et al., 1993, Retinoic acid receptor gamma 2 gene expression is up-regulated by retinoic acid in 3T3-L1 preadipocytes., Biochem. J.
Borger et al., 2000, Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-beta., Virology
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Fujishita et al., 2006, Upregulation of P2Y2 receptors by retinoids in normal human epidermal keratinocytes., Purinergic Signal.
Day et al., 2006, Retinoic acid inhibits airway smooth muscle cell migration., Am. J. Respir. Cell Mol. Biol.
Koda et al., 2007, Antiestrogenic activity of vitamin A in in vivo uterotrophic assay., Life Sci.
He et al., 2007, Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway., J. Am. Soc. Nephrol.
Wang et al., 2004, A novel retinoic acid-responsive element regulates retinoic acid-induced BLR1 expression., Mol. Cell. Biol.
Mizuguchi et al., 2006, Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60., Biol. Pharm. Bull.
Goto et al., 2011, Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment., Blood
Tomita et al., 2013, Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia., Int. J. Hematol.
Welch et al., 2011, Use of whole-genome sequencing to diagnose a cryptic fusion oncogene., JAMA
Degos et al., 2001, All trans retinoic acid in acute promyelocytic leukemia., Oncogene
Yoshida et al., 1996, Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway., Cancer Res.
Hattori H et al., 2018, Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia., PLoS One
Wang et al., 2007, Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha., Proc. Natl. Acad. Sci. U.S.A.
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Harant et al., 1996, Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB., J. Biol. Chem.
Ichikawa et al., 2015, Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene., Cancer Genet
Balusu et al., 2011, Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1., Blood
Burnett et al., 2010, The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA., Blood
Butts et al., 2005, Transforming growth factor-beta1 signaling participates in the physiological and pathological regulation of mouse inner ear development by all-trans retinoic acid., Birth Defects Res. Part A Clin. Mol. Teratol.
Xue et al., 2005, [Factors regulating expression of antiapoptosis gene survivin]., Zhongguo Shi Yan Xue Ye Xue Za Zhi
Pratt et al., 2003, Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids., J. Cell. Biochem.
Visani et al., 1996, All-trans retinoic acid and in vitro cytokine production by acute promyelocytic leukemia cells., Eur. J. Haematol.
Zirn et al., 2005, All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo., Oncogene
Youssef et al., 2004, Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers., Cancer Res.
Nakashima K et al., 2015, Xanthones from the roots of Maclura cochinchinensis var. gerontogea and their retinoic acid receptor-α agonistic activity., Bioorg Med Chem Lett
Kim H et al., 2008, Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative., Bioorg Med Chem
Vollberg TM Sr et al., 1992, Retinoic acid receptors as regulators of human epidermal keratinocyte differentiation., Mol Endocrinol
Pisani et al., 1997, In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts., Ann. Hematol.
Reynolds et al., 2000, Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide., Med. Pediatr. Oncol.
Sasaki et al., 2000, Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells., Brain Res. Mol. Brain Res.
Lee et al., 1995, Induction of 73-kDa and 90-kDa heat shock protein expression in HL60 cells during differentiation., Tohoku J. Exp. Med.
Mills et al., 2000, High FUS/TLS expression in acute myeloid leukaemia samples., Br. J. Haematol.
Steidl U et al., 2005, Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera., Ann N Y Acad Sci
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Lucena-Araujo et al., 2014, Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study., Ann. Hematol.
Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud

TRETINOIN RARRES1

Interaction Score: 6.4

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
15897880 15059893

Sources:
TEND
TRETINOIN PML

Interaction Score: 6.4

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein PML:RARA

PMIDs:
21613260 23670176 21505136 11704842 8674046 30289902

Sources:
CIViC PharmGKB FDA
TRETINOIN FUS

Interaction Score: 4.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10691862

Sources:
NCI
TRETINOIN BCOR

Interaction Score: 4.26

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute promyelocytic leukemia

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25790901

Sources:
JAX-CKB
TRETINOIN RXRG

Interaction Score: 1.87

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name tretinoin microsponge,Retin-A

Novel drug target Established target

PMIDs:
16420438 16456186 17161848 17182884 14993281

Sources:
TdgClinicalTrial TEND
TRETINOIN RXRB

Interaction Score: 1.66

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name tretinoin microsponge,Retin-A

PMIDs:
16420438 15379735 17184907 16109390 16392701

Sources:
TdgClinicalTrial TEND
TRETINOIN RARG

Interaction Score: 1.47

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Retinoic acid receptor agonist

Direct Interaction yes

Trial Name tretinoin microsponge,Retin-A

PMIDs:
10592235 1332684 11752352 8394693 10792999 17016423 17139284

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
TRETINOIN P2RY2

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18404486

Sources:
NCI
TRETINOIN RARA

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Retinoic acid receptor agonist

Fusion protein PML:RARA

PMIDs:
25838141 18511283 1318502

Sources:
DTC ChemblInteractions PharmGKB FDA
TRETINOIN MYCN

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11107126

Sources:
NCI
TRETINOIN SMAD2

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15799023

Sources:
NCI
TRETINOIN NPM1

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21719597 19965647

Sources:
CIViC
TRETINOIN CDKN1B

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10837916

Sources:
NCI
TRETINOIN RARB

Interaction Score: 0.3

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Retinoic acid receptor agonist

Direct Interaction yes

PMIDs:
15958702

Sources:
ChemblInteractions
TRETINOIN HSPA8

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8578578

Sources:
NCI
TRETINOIN IL10

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8982293

Sources:
NCI
TRETINOIN BIRC5

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16403261 14587026

Sources:
NCI
TRETINOIN FLT3

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin

Indication/Tumor Type acute promyelocytic leukemia

Response Type sensitive

PMIDs:
24981688 19965647 27626069

Sources:
JAX-CKB CIViC
TRETINOIN BCL2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9402847

Sources:
NCI
TRETINOIN CXCL8

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8900181

Sources:
NCI
TRETINOIN RXRA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16946489

Sources:
DTC
TRETINOIN CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
TRETINOIN KAT2A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRETINOIN HIF1A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRETINOIN USP1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRETINOIN CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TRETINOIN NFE2L2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18048326

Sources:
DTC NCI
TRETINOIN VDR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRETINOIN EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: TRETINOIN
- Version: 01-August-2011
Alternate Names:

TRETINOIN Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1988

Drug Class keratolytic agents

Publications:
TdgClinicalTrial: TRETINOIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of acne

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: ATRA

Version: 14-September-2017

Alternate Names:

C900 NCI drug code

Drug Info:

Publications:

Pisani et al., 1997, In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts., Ann. Hematol.

Lee et al., 1995, Induction of 73-kDa and 90-kDa heat shock protein expression in HL60 cells during differentiation., Tohoku J. Exp. Med.

Wang et al., 2007, Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha., Proc. Natl. Acad. Sci. U.S.A.

DTC: TRETINOIN

Version: 02-September-2020

Alternate Names:

CHEMBL38 ChEMBL Drug ID

Drug Info:

Publications:

Nakashima K et al., 2015, Xanthones from the roots of Maclura cochinchinensis var. gerontogea and their retinoic acid receptor-α agonistic activity., Bioorg Med Chem Lett

Kim H et al., 2008, Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative., Bioorg Med Chem

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

JAX-CKB: Tretinoin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud

Ichikawa et al., 2015, Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene., Cancer Genet

PharmGKB: tretinoin
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

CIViC: TRETINOIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Lucena-Araujo et al., 2014, Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study., Ann. Hematol.

Burnett et al., 2010, The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA., Blood

Balusu et al., 2011, Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1., Blood

TTD: Tretinoin
- Version: 2020.06.01
Alternate Names:

D02DGU TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL38
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL38
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Tretinoin
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	acute promyelocytic leukemia
Response Type	sensitive
Approval Status	Clinical Study

Trial Name	tretinoin microsponge,Retin-A
Novel drug target	Established target

Mechanism of Interaction	Retinoic acid receptor agonist
Direct Interaction	yes
Trial Name	tretinoin microsponge,Retin-A

combination therapy	Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin
Indication/Tumor Type	acute promyelocytic leukemia
Response Type	sensitive

TRETINOIN Drug Record

TRETINOIN chembl:CHEMBL38 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 15897880 15059893

Sources: TEND

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein PML:RARA

PMIDs: 21613260 23670176 21505136 11704842 8674046 30289902

Sources: CIViC PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10691862

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type acute promyelocytic leukemia Response Type sensitive Approval Status Clinical Study

PMIDs: 25790901

Sources: JAX-CKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name tretinoin microsponge,Retin-A Novel drug target Established target

PMIDs: 16420438 16456186 17161848 17182884 14993281

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: agonist (activating)

Interaction Info: Novel drug target Established target Trial Name tretinoin microsponge,Retin-A

PMIDs: 16420438 15379735 17184907 16109390 16392701

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Retinoic acid receptor agonist Direct Interaction yes Trial Name tretinoin microsponge,Retin-A

PMIDs: 10592235 1332684 11752352 8394693 10792999 17016423 17139284

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18404486

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Direct Interaction yes Mechanism of Interaction Retinoic acid receptor agonist Fusion protein PML:RARA

PMIDs: 25838141 18511283 1318502

Sources: DTC ChemblInteractions PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11107126

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15799023

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21719597 19965647

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10837916

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Retinoic acid receptor agonist Direct Interaction yes

PMIDs: 15958702

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8578578

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8982293

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16403261 14587026

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin Indication/Tumor Type acute promyelocytic leukemia Response Type sensitive

PMIDs: 24981688 19965647 27626069

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9402847

Interaction Types & Directionality:

agonist (activating)

PMIDs:
15897880 15059893

Sources:
TEND

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein PML:RARA

PMIDs:
21613260 23670176 21505136 11704842 8674046 30289902

Sources:
CIViC PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
10691862

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute promyelocytic leukemia

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25790901

Sources:
JAX-CKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name tretinoin microsponge,Retin-A

Novel drug target Established target

PMIDs:
16420438 16456186 17161848 17182884 14993281

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name tretinoin microsponge,Retin-A

PMIDs:
16420438 15379735 17184907 16109390 16392701

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Retinoic acid receptor agonist

Direct Interaction yes

Trial Name tretinoin microsponge,Retin-A

PMIDs:
10592235 1332684 11752352 8394693 10792999 17016423 17139284

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
18404486

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Retinoic acid receptor agonist

Fusion protein PML:RARA

PMIDs:
25838141 18511283 1318502

Sources:
DTC ChemblInteractions PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
11107126

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15799023

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21719597 19965647

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
10837916

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Retinoic acid receptor agonist

Direct Interaction yes

PMIDs:
15958702

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
8578578

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8982293

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16403261 14587026

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin

Indication/Tumor Type acute promyelocytic leukemia

Response Type sensitive

PMIDs:
24981688 19965647 27626069

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
9402847

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8900181

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16946489

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC